RTW vs. TPOU, PRIM, SURE, APQ, KZG, JADE, BRH, VOX, INV, and IVPB
Should you be buying RTW Biotech Opportunities stock or one of its competitors? The main competitors of RTW Biotech Opportunities include Third Point Investors (TPOU), Primorus Investments (PRIM), Sure Ventures (SURE), APQ Global (APQ), Kazera Global (KZG), Jade Road Investments (JADE), Braveheart Investment Group (BRH), Vox Valor Capital (VOX), Investment (INV), and Invesco Select Balanced Risk Alloc (IVPB). These companies are all part of the "asset management" industry.
Third Point Investors (LON:TPOU) and RTW Biotech Opportunities (LON:RTW) are both small-cap financial services companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.
RTW Biotech Opportunities has a net margin of 1,994.76% compared to RTW Biotech Opportunities' net margin of 0.00%. Third Point Investors' return on equity of 21.42% beat RTW Biotech Opportunities' return on equity.
In the previous week, RTW Biotech Opportunities had 1 more articles in the media than Third Point Investors. MarketBeat recorded 2 mentions for RTW Biotech Opportunities and 1 mentions for Third Point Investors. RTW Biotech Opportunities' average media sentiment score of 0.00 equaled Third Point Investors'average media sentiment score.
Third Point Investors has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Comparatively, RTW Biotech Opportunities has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500.
Third Point Investors received 29 more outperform votes than RTW Biotech Opportunities when rated by MarketBeat users. However, 100.00% of users gave RTW Biotech Opportunities an outperform vote while only 68.18% of users gave Third Point Investors an outperform vote.
34.5% of Third Point Investors shares are owned by institutional investors. Comparatively, 11.1% of RTW Biotech Opportunities shares are owned by institutional investors. 7.3% of Third Point Investors shares are owned by insiders. Comparatively, 12.3% of RTW Biotech Opportunities shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
RTW Biotech Opportunities has higher revenue and earnings than Third Point Investors. Third Point Investors is trading at a lower price-to-earnings ratio than RTW Biotech Opportunities, indicating that it is currently the more affordable of the two stocks.
Summary
RTW Biotech Opportunities beats Third Point Investors on 12 of the 14 factors compared between the two stocks.
Get RTW Biotech Opportunities News Delivered to You Automatically
Sign up to receive the latest news and ratings for RTW and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RTW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
RTW Biotech Opportunities Competitors List
Related Companies and Tools
